4).[3] Also, Weisholzer et al. in his study of 430 haemodialysis patients showed stroke rate was not statistically different in patients with and without atrial fibrillation when on no anti-thrombotic therapy (P = 0.22).[28] In this study, antithrombotic therapy with warfarin or salicylates was associated with a higher incidence of stroke (8.3/100 patient-years vs 2.6/100 patient-years; P = 0.0002).[28] An observational study on Dialysis Outcomes and Practice Patterns Study (DOPPS) data showed that use of warfarin was MK-1775 order associated with higher risk of stroke in patients with AF.[1]

This observation was perhaps due to confounding variables or inherent higher risk in these warfarin users or cause due to haemorrhagic stroke.[1]

Chan et al. study also showed that compared with non-use, warfarin use (44.7% of AF cohort) associated with a significantly increased risk for new stroke (hazard ratio (HR) 1.93; 95% confidence interval (CI) 1.29–2.90).[23] However, there XL765 in vitro were several limitations in this retrospective study, which makes it difficult to draw any firm conclusions. Most importantly, international normalization ratio (INR) monitoring was perhaps suboptimal in these studies that may lead to wrong interpretation. Platelet abnormalities including subnormal dense granule content Reduction in intracellular ADP and serotonin Impaired released of the platelet alpha granule protein and beta thromboglobulin Enhanced intracellular cAMP and abnormal mobilization of platelet calcium Abnormal platelet arachidonic acid metabolism Defective cyclo-oxygenase activity Abnormality of the activation-dependent binding activity of GPIIb/IIIa Increased formation of vascular (PG)12 Altered von Willebrand factor Indirectly Presence pentoxifylline of uraemic toxins, especially parathyroid hormone Anaemia/altered blood rheology Erythropoietin deficiency Specific drug treatment (e.g. non-steroidal anti-inflammatory drugs) Atherosclerosis and diffuse endothelia damage Dysfunctional activated

protein C metabolism Both elevated plasminogen activator inhibitor-1 to tissue type plasminogen activator ratios and inhibition of plasmin by increased levels of lipoprotein (a) Defects in the expression of glycoprotein GPIb (the receptor for von Willebrand factor) To the contrary, a recent large observational study showed that warfarin treatment in dialysis population was associated with a significantly decreased risk of stroke or systemic thromboembolism (HR 0.44; 95% CI 0.26–0.74; P = 0.002) but not with aspirin (HR 0.88; 95% CI 0.59–1.32; P = 0.54).[11] Studies in Table 5 were observational and heterogeneous so that the absolute risk of stroke could not be precisely determined.[1, 3, 7, 10, 20, 23, 28] As epidemiological analysis can identify only an association, causal relationships need to be shown by clinical trials. Hence, the results of epidemiological data analysis should be interpreted with caution.